Skip header and navigation

9 records – page 1 of 1.

Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Low grade evidence shows IgG and IgM antibody response correlates with neutralizingantibody titerand viral clearance, which is suggestive of protective humoral immunity inCOVID-19 patients with mild to moderate symptoms.
There is no available evidence with which to estimate the durability of this protective response. However, if the immune response to SARS-CoV-2 resembles that toward SARS-CoV, this protective humoral immunity may persist for several years.
Higher IgG antibody titersand a robustresponse were noted in severe to criticallyill patients and were associated with lower viral clearance and a worse clinical prognosis.
Low grade evidence suggests that convalescent plasma treatment may improve the clinical status of critically ill COVID-19 patients(one case series with only five patients enrolled).
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Duncan, V; Is the IgM or IgG immune response protective? 2020 Apr 11; Document no.: LAB040803 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
The majority of patients (>50%) appear to seroconvert between 8-14 days following the onset of symptoms.
Nearly all patients (>80%) seroconvert >15 days following the onset of symptoms.
The IgM response is detected earlier (median 12 days) than the IgG response (median 14 days).
Seroconversion appears to follow clinical recovery in most cases.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041401 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041401 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Moderate to strong grade evidence show the overall sensitivityrangeof IgM, IgG, and combined IgM/IgG are 48.1% to 94.1%, 64.7% to 100%, 83% to 100%, respectively.
IgM/IgG combined assay, with the posterior probability of 99.15%, has greater accuracyand sensitivity than a single IgM or IgG test.
The sensitivity of antibody tests is extremely low (~ 11.1%) in the first week following the onsetof symptoms but increasesrapidlyduring the second week.
IgG and IgM titers in patients with severe disease arehigher than those in the non-severe patients.
Antibody testsmay detect the presence of COVID-19 in asymptomatic individuals with negative rt-PCRresults.
Category
Clinical Presentation
Subject
Testing
Serology
Antibodies
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 15; Document no.: LAB041401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST rapid review report)
Similar Reviews
PH042401 RR
EPM051201 RR
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041501 RR
Question Submitted
April 15, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041501 RR
Question Submitted
April 15, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Seroconversion occurs in majority of COVID-19 patients from the second week following symptomonseton.
Between 7.8 -43.6% of suspect cases and 4.7% of asymptomatic individuals with negative nucleic acid test (rt-PCR) test positive for antibodies against SARS-CoV-2.
An increase in antibody titrescorrelates with a neutralizing antibody response and positive recovery of COVID-19 patients with mild to moderate symptoms.
Although higher antibody titreand more robust antibody response are observed in severe and critically ill patients, those antibodies may not effectively clear virus and higher antibody levels may be associated with a worse clinical progress.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 17; Document no.: LAB041501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB042201 RR
Question Submitted
April 22, 2020
Date Completed
April 23, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB042201 RR
Question Submitted
April 22, 2020
Date Completed
April 23, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
For COVID-19 there are no published data to identify optimal population sampling methods, however, a population-based sample in which testing is performed for both rt-PCR and serology might be recommended. There are also opportunities to examine innovative sampling strategies being used in pilot studies underway in other jurisdictions.
Category
Diagnostics
Epidemiology
Subject
Testing
Public Health
Population
All
Clinical Setting
Community
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Reeder, B; Duncan, V. What sampling method is most appropriate for population testing? 2020 Apr 23; Document no.: LAB042201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB042202 RR
Question Submitted
April 22, 2020
Date Completed
April 25, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB042202 RR
Question Submitted
April 22, 2020
Date Completed
April 25, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Low grade evidence suggests that SARS-CoV-2 may persist within a population and lead to recrudescent outbreaks in winter months which may include the re-infection of previously infected individuals. · Population monitoring by means of repeated cross-sectional surveys and/or longitudinal cohort studies is strongly advised by WHO
Category
Diagnostics
Epidemiology
Subject
Testing
Public Health
Population
All
Clinical Setting
Community
Priority Level
Level 3 completed within 2-3 days
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. What frequency of repeat population screening will be required? 2020 Apr 25; Document no.: LAB042202 RR. In: COVID19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB040701v2 RR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB040701v2 RR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Key Findings
COVID-19 is primarily transmitted by symptomatic patientsand presymptomatic individuals.·Moderate grade evidence estimates that approximately 20% of COVID-19 transmission may bedue to that from presymptomatic individuals.However, estimates range from 6.4% -47%.·Asymptomatic individuals and environmental contaminationappear to contributelessto disease transmission,with estimated proportionsof 6% and 10%, respectivelyfrom modelling studies
Category
Clinical Presentation
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Asymptomatic
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B; What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? 2020 May 8; Document no.: LAB040701v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST rapid review report)
Similar Reviews
EPM051301 RR
Review History
LAB040701 RR: April 7, 2020
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041601v2 RR
Question Submitted
April 16, 2020
Date Completed
May 19, 2020
Status
5. Updated review
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041601v2 RR
Question Submitted
April 16, 2020
Date Completed
May 19, 2020
Status
5. Updated review
Research Team
Laboratory
Key Findings
Patients with higher and prolonged IgM antibodies are associated with more severe illness, poor recovery, and prolonged viral shedding (some patients may shed virus for more than 30 days).
Patients who respond weakly to IgG have higher viral clearance rate than strong responders.
There were no reports with direct information regarding infectiousness of patients.
Category
Diagnostics
Clinical Presentation
Subject
Transmission
Antibodies
Natural History
Population
All
Cite As
Vanstone, J; Reeder, B; Duncan, V. What is the relationship between antibody development and viral shedding and infectiousness? 2020 May 19; Document no.: LAB041601v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Review History
LAB041601 RR: April 16, 2020
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB040802v3 RR
Question Submitted
April 8, 2020
Date Completed
June 2, 2020
Status
5. Updated review
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB040802v3 RR
Question Submitted
April 8, 2020
Date Completed
June 2, 2020
Status
5. Updated review
Research Team
Laboratory
Key Findings
Several references provide estimates of the proportion of HCW infected with SARS-CoV2 that range from 0.9% -20%. A recent review from Alberta Health Services that examined the COVID-19 rt-PCR test results among HCW indicates that in that province 2.4% of physicians and 0.9% of non-MD HCW who were tested were positive for SARS-CoV-2 compared to 3.5% of the general population.
In the studies reviewed, the majority of cases are confirmed by RT-PCR, while only one reference also used serology testing.
Category
Diagnostics
Administration
Subject
Testing
Serology
Polymerase Chain Reaction
Health Personnel
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Vanstone, J; Reeder, B; Duncan, V; Howell-Spooner, B. What proportion of healthcare workers are rt-PCR positive and IgM or IgG positive? 2020 Jun 2; Document no.: LAB040802v3 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 10 p. (CEST rapid review report)
Review History
LAB040802v2 RR: May 19, 2020
LAB040802 RR: April 9, 2020
Related Documents
Documents
Less detail

9 records – page 1 of 1.